Clinical Trials Directory

Trials / Completed

CompletedNCT04639505

Predictive Value of New AMH Test Method for Ovarian Response

Predictive Value of New AMH Test Method for Ovarian Response in Patients With IVF/ICSI

Status
Completed
Phase
Study type
Observational
Enrollment
454 (actual)
Sponsor
Reproductive & Genetic Hospital of CITIC-Xiangya · Academic / Other
Sex
Female
Age
20 Years – 45 Years
Healthy volunteers

Summary

In China, the incidence of infertility is about 15%, and patients need to use assisted reproductive technology (ART) to obtain pregnancy. It is particularly important to accurately predict the patient's ovarian response before initiating controlled ovulation hyperstimulation (COH). At present, the commonly used AMH detection method is enzyme-linked immunoassay (ELISA), and it has obtained the normal reference range for ovarian response. In recent years, with the development of detection technology, chemiluminescence immunoassay(CLIA) detection reagents have been successively used for the detection of AMH. However, there are few studies on the comparison of these two detection methods. The predictive value of the new method on ovarian response was lack. Therefore, by comparing the two methods of ELISA and CLIA detection of AMH levels in this study, the predictive value of poor ovarian response (the number of retrieved oocyte ≤ 3) and high response (the number of retrieved oocyte ≥ 15) in IVF/ICSI stimulation cycle was analyzed. In order to provide more reference basis for individualized COH, the AMH cutoff value of low and high ovarian response by the new method predicts was analyzed. At the same time, the prediction value of the two methods is compared to determine whether the new CLIA is suitable for clinical application.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTELISAELISA kit detecting the serum AMH level
DIAGNOSTIC_TESTChemiluminescenceCLIA method detecting the serum AMH level

Timeline

Start date
2020-11-15
Primary completion
2021-06-03
Completion
2021-09-30
First posted
2020-11-20
Last updated
2022-01-13

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04639505. Inclusion in this directory is not an endorsement.